Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer
Abstract
To the Editor: We have several concerns with regard to the ASCENT-03 trial by Cortés et al. (Nov. 13 issue). 1 First is the use of physician’s choice in determining the chemotherapy regimen for the chemotherapy group. 2 Can the authors reveal what proportion of patients had previously received anthracycline-based chemotherapy, a key treatment option for triple-negative breast cancer, 3 or reasons why patients were deemed to be ineligible for this treatment? Second, can the authors provide postprogression treatment data? Did any patients receive anthracyclines or even inhibitors of programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) after disease . . .
Fields of Study & Subjects
HER2/EGFR in Cancer Research
Protease and Inhibitor Mechanisms
Cell Adhesion Molecules Research
Publication details
- Journal / source
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Volume
- 394
- Issue
- 6
- Pages
- 620–621
- Publication date
- 4 February 2026
- Language
- EN